Immunomic TherapeuticsImmunomic Therapeutics
Immunomic TherapeuticsImmunomic Therapeutics
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us

Media

  • Highlights
  • Press Releases
  • Events
  • News
  • Articles
  • Posters
  • ASCO 2017 Annual Meeting

    Events Past Events
    June 2-6, McCormick Place, Chicago, IL The ASCO Annual Meeting offers informative educational and scientific sessions that highlight the latest in cancer care treatments. VIEW PRELIMINARY PROGRAM Check out the Preliminary
    Read more
  • Skin Vaccination Summit

    Events Past Events
    22-24 May 2017, Leiden University Medical Centre, Leiden, The Netherlands Recognition of the skin by vaccinologists as an ideal anatomical target has gathered momentum in the past decade. The premise
    Read more
  • Immunology 2017

    Events Past Events
    Meet us in D.C.! May 12-16, 2017 Washington Convention Center Great science awaits you at this, the largest annual gathering of immunologists worldwide. At IMMUNOLOGY 2017™, you’ll hear from global
    Read more
  • STIC 2017 Annual Meeting and Pre Conference Programs

    Events Past Events
    Wednesday, November 8 - Sunday, November 12, 2017  Save the Date! The Society for Immunotherapy of Cancer (SITC) cordially asks you to save the date of our 32nd Annual Meeting
    Read more
  • 2017 BIO International Convention

    Events Past Events
    BIO Returns to California Location: San Diego Convention Center; 111 W Harbor Dr., San Diego, CA 92101 There’s no better place to connect with biotech’s top people and most innovative
    Read more
  • Immunomic Therapeutics licenses Hopkins-developed vaccine technology for $300 million

    Press
    Immunomic Therapeutics, a biotechnology company developing a new type of vaccine based on Johns Hopkins research, has reached a $300 million deal licensing its technology to Japanese company Astellas Pharma.
    Read more
  • BioWorld’s Partner in Focus: Immunomic Therapeutics, Inc.

    Highlights
    THE REMARKABLE SCIENCE BEHIND LAMP TECHNOLOGY – AND ITS POTENTIAL TO TREAT HUMAN DISEASE   The body’s own immune system is its best defense against everything from allergies to cancer
    Read more
  • Immunomic Therapeutics (ITI) Named “Company of the Year” by the Tech Council of Maryland

    Press Releases
    ROCKVILLE, Md., May 16, 2016 /PRNewswire/ -- At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the
    Read more
  • Immunomic Therapeutics Gives Back to Maryland Biotech Community

    Press Releases
    November 08, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery
    Read more
  • Fierce Pharma Article on Reprogramming the Immune System To Fight Cancer

    Highlights
    https://www.fiercepharma.com/sponsored/reprogramming-immune-system-to-fight-cancerhttps://www.fiercepharma.com/sponsored/reprogramming-immune-system- Reprogramming the Immune System To Fight Cancer Sponsored by Immunomic Therapeutics, Inc. Nov 14, 2016 12:00am By Teri Heiland, Ph.D and Bill Watt, Ph.D. Cancer immunotherapy marks a turning
    Read more
  • The Japan Times Highlights Immunomics’ LAMP-Vax

    Highlights
    Clouds of pollen emanate from cedar trees in Sagamihara, Kanagawa Prefecture, in 2005. | KYODO LIFESTYLE When pollen attacks! Experts reveal new approaches to combating hay fever BY TOMOKO OTAKE
    Read more
  • Washington Post – Chasing Cancer Summit

    Events Past Events
    Immunomic is pleased to share that CEO Dr. Bill Hearl served as a panelist during The Washington Post’s Chasing Cancer Summit in Washington, D.C. on Tuesday, Dec. 7th. The event was focused
    Read more
1234567891011121314151617181920212223242526
← Previous pageNext page →

Content
  • Pipeline
  • Partnerships
  • Team
  • Media
  • Contact Us
Careers
  • Careers
  • Compensation & Benefits
  • Culture & Beliefs
Policies
  • Expanded Access Policy
  • Privacy Policy
Social
  • Facebook
  • X / Twitter
  • Youtube
Telephone

+1.301.968.3501

Address

15010 Broschart Road

Rockville, MD 20850

© 2020 Immunomic Therapeutics, Inc. All Rights Reserved.